通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

000766 通化金马

已收盘 02-09 15:00:00

{"stockData":{"symbol":"000766","market":"SZ","secType":"STK","nameCN":"通化金马","latestPrice":23.65,"timestamp":1770620601000,"preClose":23,"halted":0,"volume":18044768,"delay":0,"changeRate":0.0283,"floatShares":966000000,"shares":966000000,"eps":0.0595,"marketStatus":"已收盘","change":0.65,"latestTime":"02-09 15:00:00","open":23.15,"high":23.75,"low":22.78,"amount":421000000,"amplitude":0.0422,"askPrice":23.66,"askSize":31,"bidPrice":23.65,"bidSize":237,"shortable":0,"etf":0,"ttmEps":0.0595,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770687000000},"marketStatusCode":5,"adr":0,"adjPreClose":23,"symbolType":"stock","openAndCloseTimeList":[[1770600600000,1770607800000],[1770613200000,1770620400000]],"highLimit":25.3,"lowLimit":20.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":966494707,"isCdr":false,"pbRate":9.66,"roa":"--","peRate":397.478992,"roe":"1.1%","epsLYR":0.06,"committee":-0.68272,"marketValue":22858000000,"turnoverRate":0.0187,"status":0,"floatMarketCap":22846000000},"requestUrl":"/m/hq/s/000766","defaultTab":"news","newsList":[{"id":"2607584058","title":"股市必读：通化金马（000766）1月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2607584058","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607584058?lang=zh_cn&edition=full","pubTime":"2026-01-30 02:43","pubTimestamp":1769712189,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘，通化金马报收于26.6元，上涨2.23%，换手率1.91%，成交量18.48万手，成交额4.86亿元。董秘最新回复投资者： 新药获批前，公司会进行所谓二级市场黄金坑的布局吗董秘： 您好，公司严格遵守相关法律法规开展经营活动。交易信息汇总资金流向1月29日主力资金净流入573.75万元；游资资金净流出371.39万元；散户资金净流出202.36万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000001557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","000766","BK0060","BK0239"],"gpt_icon":0},{"id":"2603719205","title":"通化金马：琥珀八氢氨吖啶片进入最后审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2603719205","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603719205?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:48","pubTimestamp":1768276087,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)01月12日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘董高管，新年伊始恭喜贵司创新药审评又进一步，那么接下来到那个环节了通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作并已按要求提供各专业研究资料，进入最后审评环节，各项工作进展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300016888.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","000766","BK0077"],"gpt_icon":0},{"id":"2601036490","title":"通化金马：新药已完成综合审评工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036490","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601036490?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:52","pubTimestamp":1767876750,"startTime":"0","endTime":"0","summary":"按照公司之前公告，12月12日机构调研公司的问答记录显示，公司新药当前已经处于综合审评阶段，并且按照CDE规定完成了临床、统计和药学方面的专家综合审评会议，公司完成了上市申请的各项工作。通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作，进入最后审评环节，各项工作进展正常。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800037007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0077","000766"],"gpt_icon":0},{"id":"2601038698","title":"通化金马：琥珀八氢氨吖啶片进入最后审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2601038698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601038698?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:51","pubTimestamp":1767790270,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)01月06日在投资者关系平台上答复投资者关心的问题。投资者提问：公司新药进展如何了？通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片主要用于治疗轻中度阿尔茨海默病。目前该新药已完成综合审评工作，进入最后审评环节，各项工作进展正常。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700036824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000766","BK0077","BK0060"],"gpt_icon":0},{"id":"2595719300","title":"股市必读：通化金马（000766）12月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2595719300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595719300?lang=zh_cn&edition=full","pubTime":"2025-12-31 00:59","pubTimestamp":1767113948,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，通化金马报收于27.39元，下跌1.3%，换手率1.25%，成交量12.08万手，成交额3.33亿元。董秘最新回复投资者： 请问新药的审批到什么程度了？有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。交易信息汇总资金流向12月30日主力资金净流出4669.53万元；游资资金净流入1477.83万元；散户资金净流入3191.71万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100000925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000766","BK0060","BK0077"],"gpt_icon":0},{"id":"2595792752","title":"通化金马：新药进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2595792752","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595792752?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:53","pubTimestamp":1767099187,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)12月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问新药的审批到什么程度了？按照规定还需要多长时间？通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000040903.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0239","BK0077","BK0060"],"gpt_icon":0},{"id":"2591907984","title":"通化金马：琥珀八氢氨吖啶片进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2591907984","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591907984?lang=zh_cn&edition=full","pubTime":"2025-12-16 20:51","pubTimestamp":1765889469,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马12月15日在投资者关系平台上答复投资者关心的问题。那么想请问董秘，金马药业目前在审的一类新药琥珀八氢氨吖啶片，是否收到CDE的发补通知？烦请董秘正面回复，毕竟这个问题的答复投资者，并非信披违规。通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600038053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0060","000766","BK0239"],"gpt_icon":0},{"id":"2590151355","title":"通化金马：琥珀八氢氨吖啶片进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2590151355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590151355?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:48","pubTimestamp":1765457318,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：你好董秘 ，最近新药审核进度怎么样了有传说和常山药业一样需要发补  以及贵司张董讲指日可待 这个时间点为什么不和中小股东多沟通下通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100038203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000766","BK0239","BK0077"],"gpt_icon":0},{"id":"2586738287","title":"通化金马（000766）公司公告披露股东会决议，11月28日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738287","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586738287?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:19","pubTimestamp":1764339583,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，通化金马报收于27.26元，较前一交易日下跌1.62%，最新总市值为263.47亿元。该股当日开盘27.7元，最高27.7元，最低27.15元，成交额达2.76亿元，换手率为1.05%。近日，通化金马药业集团股份有限公司发布2025年第四次临时股东会决议公告。公告称，公司于2025年11月28日召开2025年第四次临时股东会，审议通过了续聘2025年度审计机构、对公司下属子公司提供担保额度预计、全资子公司为母公司提供担保额度预计三项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800040088.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0060","BK0077","BK0239"],"gpt_icon":0},{"id":"2586282135","title":"通化金马：琥珀八氢氨吖啶片进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2586282135","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586282135?lang=zh_cn&edition=full","pubTime":"2025-11-26 11:48","pubTimestamp":1764128890,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)11月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司领导，你好，前段时间公司回答投资者问题说临近审批，最近回答又改成评审正常进行中，造成股价几天大跌，难道不应该是先回答是正常进行中再才是临近审批，难道评审有问题？通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入了综合审评环节，各项审评工作正常进行中。有关新药的重大信息，均会在指定信息披露媒体发布，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600013304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000766","BK0239","BK0077"],"gpt_icon":0},{"id":"2584981008","title":"通化金马：琥珀八氢氨吖啶片进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2584981008","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584981008?lang=zh_cn&edition=full","pubTime":"2025-11-18 15:48","pubTimestamp":1763452093,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马11月17日在投资者关系平台上答复投资者关心的问题。我们关注到公司的琥珀八氢氨吖啶片是治疗阿尔茨海默病的重磅创新药。通化金马回复：您好，我公司研制的化学1类新药琥珀八氢氨吖啶片，已完成各项专业审评工作，进入综合审评环节，各项审评工作处于正常进行中。公司将继续深度布局神经领域的产品管线和平台建设，有关新药的相关信息公司将根据有关规定和要求予以披露，请投资者关注公司公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800018973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000766","BK0077","BK0060"],"gpt_icon":0},{"id":"2584852984","title":"通化金马：新药生产已准备就绪","url":"https://stock-news.laohu8.com/highlight/detail?id=2584852984","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584852984?lang=zh_cn&edition=full","pubTime":"2025-11-18 15:48","pubTimestamp":1763452089,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)11月17日在投资者关系平台上答复投资者关心的问题。投资者提问：公司琥珀八氢氨吖啶片III期临床数据优异（ADAS-Cog改善3.98分），目前审评已进入综合环节，能否介绍后续商业化准备情况？如产能、渠道布局如何体现＇高质量创新药＇定位？通化金马回复：您好，目前按公司创新转型发展的战略部署，新药的生产已准备就绪，商业化运作已完成相关筹划。有关新药的相关信息公司将根据有关规定和要求予以披露，请投资者关注公司公告。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800018972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0077","BK0239","BK0060"],"gpt_icon":0},{"id":"2582995003","title":"股市必读：通化金马（000766）11月11日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2582995003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582995003?lang=zh_cn&edition=full","pubTime":"2025-11-12 02:08","pubTimestamp":1762884494,"startTime":"0","endTime":"0","summary":"截至2025年11月11日收盘，通化金马报收于27.72元，上涨1.95%，换手率1.87%，成交量18.02万手，成交额4.96亿元。董秘最新回复投资者： 恭喜贵公司对外设立子公司在创新药产业持续深耕，是否意味着贵公司近期将有新的重大新药项目投资？还是围绕老年痴呆症领域吗？请贵公司正面回应，谢谢！当日关注点来自交易信息汇总：11月11日主力资金净流入1517.96万元，呈现明显吸筹迹象。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200001076.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0239","BK0077","BK0060"],"gpt_icon":0},{"id":"2581091812","title":"通化金马（000766）披露拟设立全资子公司，11月06日股价上涨4.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091812","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091812?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:08","pubTimestamp":1762438102,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，通化金马报收于28.19元，较前一交易日上涨4.8%，最新总市值为272.45亿元。该股当日开盘26.9元，最高28.23元，最低26.61元，成交额达7.17亿元，换手率为2.7%。根据公司近日发布的公告，通化金马药业集团股份有限公司于2025年11月6日召开第十一届董事会第八次临时会议，审议通过关于对外投资设立全资子公司的议案。公司拟使用自有或自筹资金人民币7,000万元设立全资子公司桂林金马创新投资有限公司。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","000766","BK0060"],"gpt_icon":0},{"id":"2581068037","title":"通化金马最新公告：拟7000万元设立全资子公司桂林金马创新投资有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2581068037","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581068037?lang=zh_cn&edition=full","pubTime":"2025-11-06 18:09","pubTimestamp":1762423780,"startTime":"0","endTime":"0","summary":"通化金马(000766.SZ)公告称，公司拟使用自有或自筹资金7000万元投资设立全资子公司桂林金马创新投资有限公司，旨在加强开展创新药产业的并购和布局，提升公司核心竞争力。该子公司将纳入公司合并报表范围，不会对公司当前财务状况及经营成果产生重大不利影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600028905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000766","BK0060","BK0077"],"gpt_icon":0},{"id":"2579657651","title":"通化金马：新药进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2579657651","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579657651?lang=zh_cn&edition=full","pubTime":"2025-10-30 11:48","pubTimestamp":1761796105,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)10月29日在投资者关系平台上答复投资者关心的问题。投资者提问：截至目前综合审批与行政审批是正常进行中，还是停滞状态，此问只涉及目前状态，公司有义务直面回答。通化金马回复：您好，目前我公司新药已完成各项专业审评工作进入综合审评环节，审批工作正常进行中，已经处于临近审批阶段。公司新药琥珀八氢氨吖啶片审评进展请以药审中心公示信息为准，如公司发生达到信息披露标准的事项，公司将根据相关信息披露的规定和要求予以披露。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000019219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","000766","BK0060"],"gpt_icon":0},{"id":"2578588674","title":"通化金马（000766）2025年三季报简析：净利润同比增长4.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578588674","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578588674?lang=zh_cn&edition=full","pubTime":"2025-10-28 06:03","pubTimestamp":1761602611,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期通化金马发布2025年三季报。根据财报显示，通化金马净利润同比增长4.35%。截至本报告期末，公司营业总收入8.92亿元，同比下降7.88%，归母净利润2496.35万元，同比上升4.35%。按单季度数据看，第三季度营业总收入2.42亿元，同比下降24.15%，第三季度归母净利润815.95万元，同比下降28.77%。去年的净利率为4.23%，算上全部成本后，公司产品或服务的附加值不高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800006343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766"],"gpt_icon":0},{"id":"2578654540","title":"股市必读：通化金马(000766)股东户数3.82万户，较上期减少3.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578654540","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578654540?lang=zh_cn&edition=full","pubTime":"2025-10-27 03:19","pubTimestamp":1761506349,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，通化金马报收于25.2元，下跌0.47%，换手率1.55%，成交量15.0万手，成交额3.79亿元。来自股本股东变化：截至2025年9月30日，通化金马股东户数为3.82万户，较6月30日减少3.2%，户均持股数量上升至2.53万股。交易信息汇总资金流向10月24日主力资金净流出1226.48万元；游资资金净流出123.78万元；散户资金净流入1350.25万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700000831.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","000766","BK0060","BK0239"],"gpt_icon":0},{"id":"2577686355","title":"通化金马：新药已完成专业审评进入综合审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2577686355","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577686355?lang=zh_cn&edition=full","pubTime":"2025-10-24 11:48","pubTimestamp":1761277684,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：新药审批到那一步了？新药上市还要多久？通化金马回复：您好，目前我公司新药已完成各项专业审评工作，进入综合审评环节，临近审批阶段。公司新药琥珀八氢氨吖啶片审评进展请以药审中心公示信息为准，如公司发生达到信息披露标准的事项，公司将根据相关信息披露的规定和要求予以披露。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400016546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000766","BK0060","BK0239","BK0077"],"gpt_icon":0},{"id":"2569763426","title":"通化金马：新药进入综合审评环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2569763426","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569763426?lang=zh_cn&edition=full","pubTime":"2025-09-23 11:48","pubTimestamp":1758599287,"startTime":"0","endTime":"0","summary":"证券之星消息，通化金马(000766)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：公司是否有收到药监局关于新药的发补通知？通化金马回复：您好，目前我公司新药已经完成各项专业审评工作进入综合审评环节，已经处于临近审批阶段。公司新药琥珀八氢氨吖啶片审评进展请以药审中心公示信息为准，如公司发生达到信息披露标准的事项，公司将根据相关信息披露的规定和要求予以披露。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300015392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","000766","BK0239","BK0077"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770665536540,"stockEarnings":[{"period":"1week","weight":-0.0574},{"period":"1month","weight":-0.0667},{"period":"3month","weight":-0.1468},{"period":"6month","weight":0.0155},{"period":"1year","weight":0.5725},{"period":"ytd","weight":-0.1397}],"compareEarnings":[{"period":"1week","weight":0.0267},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0301},{"period":"6month","weight":0.1194},{"period":"1year","weight":0.248},{"period":"ytd","weight":0.0389}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"通化金马药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38232人(较上一季度减少3.20%)","perCapita":"25266股","listingDate":"1997-04-30","address":"吉林省通化市二道江区金马路999号","registeredCapital":"96649万元","survey":"　　通化金马药业集团股份有限公司的主营业务是医药产品的研发、生产与销售。公司的主要产品是中成药、生化药、原料药、其他。公司2019年公司被评定为高新技术企业，荣获“中华民族医药百强品牌企业”、2015年度最具资本力企业奖、2017创新中国十大发展潜力企业、“2022-2023年度中国医药制造业百强”、2023年度中国化药企业TOP100等称号。","listedPrice":7.23},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供通化金马(000766)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"通化金马,000766,通化金马股票,通化金马股票老虎,通化金马股票老虎国际,通化金马行情,通化金马股票行情,通化金马股价,通化金马股市,通化金马股票价格,通化金马股票交易,通化金马股票购买,通化金马股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"通化金马(000766)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供通化金马(000766)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}